Haisco Pharmaceutical Group Co., Ltd.

002653

CNE100001BC7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
27.19 ^CNY	+2.84%		+1.38%	+17.45%

Apr. 10	Haisco Pharma Gets Nod to Trial Asthma Drug	MT
Apr. 01	Haisco Pharma Gets Nod to Trial HSK16149 Capsule as Central Neuropathic Pain Drug	MT

Haisco Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for 2021

April 27, 2022 at 03:33 pm EDT

Haisco Pharmaceutical Group Co., Ltd. proposed final cash dividend per 10 shares (tax included) of CNY 1.85000000 for 2021.

Latest news about Haisco Pharmaceutical Group Co., Ltd.

Haisco Pharma Gets Nod to Trial Asthma Drug	Apr. 10	MT
Haisco Pharma Gets Nod to Trial HSK16149 Capsule as Central Neuropathic Pain Drug	Apr. 01	MT
Haisco Pharma's Unit Gets Nod to Trial Drug for Hemolytic Diseases	Mar. 25	MT
Haisco Pharma's Unit Gets Nod to Trial Tumor Drug Candidate	Feb. 28	MT
Haisco Pharma to Set Up New Subsidiary in China’s Tibet Region	Jan. 18	MT
Haisco Pharmaceutical Signs $462 Million Deal with Italy’s Chiesi Farmaceutici	Nov. 21	MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Haisco Pharmaceutical Group Co., Ltd. Announces Management Changes	23-08-27	CI
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-16	CI
Haisco Pharmaceutical's Unit Gets Greenlight to Trial Diabetes Drug	23-08-14	MT
Haisco Pharma's Rupatadine Fumarate Tablets Passes Regulator's Evaluation	23-08-02	MT
Haisco Pharma’s Blood Clot Drug Passes Generic Consistency Evaluation in China	23-07-24	MT
Haisco Pharma Unit Gets Certification for Formula Food	23-06-27	MT
Haisco Pharma Gets Nod for HSK31679 Tablet Trial	23-06-26	MT
Haisco Pharma Unit Registers Nutritional Formula Food	23-05-17	MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Haisco Pharma Unit Gets Certificate for Two Food Supplements	23-04-17	MT
Haisco Pharmaceutical Wins Regulatory Nod to Trial Prostate Cancer Drug	23-04-06	MT
Haisco Pharmaceutical Gets Nod for China Clinical Trial of Lung Cancer Drug; Shares Jump 3%	23-03-16	MT
Haisco Pharmaceutical Wins Nod to Start Phase II Clinical Trial of Liver Disease Drug	23-03-15	MT
Haisco Pharmaceutical Unit's Compound Amino Acid Injection Passes Regulator's Consistency Evaluation; Shares Jump 4%	23-02-08	MT
Haisco Pharmaceutical Group Co., Ltd. announced that it has received CNY 800 million in funding from Jinan Jiangshan Investment Partnership Enterprise (Limited Partnership), JPMorgan Chase Bank, National Association, Fullgoal Fund Management Co., Ltd.	23-01-11	CI
Haisco Pharmaceutical to Hold Second Phase of Respiratory Drug Trial	22-11-17	MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI

Chart Haisco Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Haisco Pharmaceutical Group Co., Ltd.

More charts

Haisco Pharmaceutical Group Co.,Ltd., formerly Xizang Haisco Pharmaceutical Group Co., Ltd., is a China-based company principally engaged in the research, development, manufacture and sale of new drugs and high-end medical instrument. The Companyâs main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-04-17 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.19

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HAISCO PHARMACEUTICAL GROUP CO., LTD.	+17.45%	4.03B
ELI LILLY AND COMPANY	+28.79%	673B
NOVO NORDISK A/S	+24.81%	551B
JOHNSON & JOHNSON	-7.64%	348B
MERCK & CO., INC.	+15.00%	317B
ABBVIE INC.	+5.99%	288B
ASTRAZENECA PLC	+2.47%	210B
NOVARTIS AG	-0.02%	204B
ROCHE HOLDING AG	-9.98%	195B
PFIZER, INC.	-11.71%	145B

Other Pharmaceuticals